Please ensure Javascript is enabled for purposes of website accessibility

Why Enochian BioSciences Was a Winner on Monday

By Eric Volkman - Jun 21, 2021 at 5:31PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company scores an exclusive license for new potential coronavirus treatment technology.

What happened

Biotech Enochian BioSciences (ENOB -4.30%) enjoyed a nice share price lift on Monday. The small-cap stock rocked 12% higher at one point, although it ultimately cooled down to a 1.2% gain on the day.

So what

That morning, Enochian announced that it had acquired an exclusive license for a novel approach for treating coronaviruses, such as SARS-CoV-2 (the one that causes COVID-19), and influenza.

In the company's words, this technology "tricks the viruses to trigger the cells it infects to commit suicide instead of becoming a virus-making factory."

A researcher studying a sample in a petri dish.

Image source: Getty Images.

Enochian explained that this technique is effected through a nanoparticle, which gives scope for either rapid treatment of an infection, or an "ambush" in which it effectively waits in a cell for infection, then strikes. This technology was developed by the biotech's co-founder Serhat Gumrukcu.

While SARS-CoV-2 hospitalizations and fatalities are down considerably throughout the U.S., there are regions both here and abroad where the coronavirus is still on the rise. Additionally, though there are several vaccines available to inoculate against it, so far there is only one drug -- Gilead Sciences' (GILD -0.47%) Veklury, or remdesivir -- approved by the FDA for use in its treatment.

Now what

Enochian said it will submit, in the proximate future, a request with the FDA for a pre-Investigator New Drug meeting. This is one of three types of investigational new drug (IND) submittals; these are formal applications that allow novel treatments or technologies to undergo clinical testing on human subjects.


Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Enochian Biosciences, Inc. Stock Quote
Enochian Biosciences, Inc.
$2.45 (-4.30%) $0.11
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$66.02 (-0.47%) $0.31

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.